Investors Purchase High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was the recipient of unusually large options trading on Monday. Stock traders purchased 15,741 call options on the stock. This represents an increase of approximately 36% compared to the typical volume of 11,557 call options.

Institutional Trading of Capricor Therapeutics

Several institutional investors have recently added to or reduced their stakes in CAPR. Farther Finance Advisors LLC purchased a new position in shares of Capricor Therapeutics during the third quarter valued at approximately $28,000. Parkside Financial Bank & Trust purchased a new position in Capricor Therapeutics during the 3rd quarter valued at $36,000. Russell Investments Group Ltd. boosted its holdings in Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the period. Tower Research Capital LLC TRC increased its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 4,976 shares during the period. Finally, Citizens Financial Group Inc. RI bought a new stake in shares of Capricor Therapeutics during the first quarter worth $95,000. Institutional investors own 21.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Oppenheimer boosted their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday. Industrial Alliance Securities set a $48.00 price objective on Capricor Therapeutics in a research note on Wednesday. Finally, Roth Capital upped their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Trading Up 12.8%

NASDAQ:CAPR traded up $3.44 during midday trading on Monday, hitting $30.33. 3,730,161 shares of the company traded hands, compared to its average volume of 2,171,547. The firm has a market capitalization of $1.39 billion, a P/E ratio of -17.04 and a beta of 0.62. The firm’s fifty day moving average is $7.59 and its 200-day moving average is $8.22. Capricor Therapeutics has a 12-month low of $4.30 and a 12-month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). On average, research analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.